Literature DB >> 31841621

Molecular Dynamics Simulations Applied to Structural and Dynamical Transitions of the Huntingtin Protein: A Review.

Sanda Nastasia Moldovean1, Vasile Chiş1.   

Abstract

Over the recent years, Huntington's disease (HD) has become widely discussed in the scientific literature especially because at the mutant level there are several contradictions regarding the aggregation mechanism. The specific role of the physiological huntingtin protein remains unknown, due to the lack of characterization of its entire crystallographic structure, making the experimental and theoretical research even harder when taking into consideration its involvement in multiple biological functions and its high affinity for different interacting partners. Different types of models, containing fewer (not more than 35 Qs) polyglutamine residues for the WT structure and above 35 Qs for the mutants, were subjected to classical or advanced MD simulations to establish the proteins' structural stability by evaluating their conformational changes. Outside the polyQ tract, there are two other regions of interest (the N17 domain and the polyP rich domain) considered to be essential for the aggregation kinetics at the mutant level. The polymerization process is considered to be dependent on the polyQ length. As the polyQ tract's dimension increases, the structures present more β-sheet conformations. Contrarily, it is also considered that the aggregation stability is not necessarily dependent on the number of Qs, while the initial stage of the aggregation seed might play the decisive role. A general assumption regarding the polyP domain is that it might preserve the polyQ structures soluble by acting as an antagonist for β-sheet formation.

Entities:  

Keywords:  Huntington’s disease; molecular dynamics; mutant HTT; neurodegeneration; polyglutamine; trinucleotide repeats

Mesh:

Substances:

Year:  2019        PMID: 31841621     DOI: 10.1021/acschemneuro.9b00561

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  3 in total

1.  Novel Substituted Benzothiazole Compounds for Treating Huntington's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-03-31       Impact factor: 4.345

2.  Novel Substituted Monocyclic Heteroaryl Compounds for Treating Huntington's Disease.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2020-12-10       Impact factor: 4.345

3.  Synthesis and Evaluation of a Fluorine-18 Radioligand for Imaging Huntingtin Aggregates by Positron Emission Tomographic Imaging.

Authors:  Tanpreet Kaur; Allen F Brooks; Alex Lapsys; Timothy J Desmond; Jenelle Stauff; Janna Arteaga; Wade P Winton; Peter J H Scott
Journal:  Front Neurosci       Date:  2021-12-02       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.